{"aliases":[{"type":"Synonym","name":"dostarlimab"},{"type":"USBrandName","name":"Jemperli"},{"type":"CodeName","name":"TSR-042"},{"type":"CodeName","name":"ANB011"},{"type":"CodeName","name":"TSR042"},{"type":"CodeName","name":"TSR 042"},{"type":"Synonym","name":"immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer"},{"type":"CASRegistryName","name":"2022215-59-2"}],"definition":{"html":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab-gxly binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","text":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab-gxly binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/dostarlimab-gxly","text":"Dostarlimab-gxly"},"nciConceptId":"C126799","nciConceptName":"Dostarlimab","termId":780223,"name":"dostarlimab-gxly","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"dostarlimab"}